Treace Medical Concepts Inc.

Treace Medical Concepts, Inc., often referred to as Treace Medical Concepts or Treace, is a publicly traded orthopaedic medical device company headquartered in Ponte Vedra Beach, Florida, U.S.. The company was formally established in January 2014, evolving from a medical device consulting firm founded in 2013. Traded on Nasdaq under the ticker symbol "TMCI," Treace Medical Concepts reported a full-year 2025 revenue of $212.7 million and employed approximately 450 individuals as of 2026. Its market capitalization was around $176 million as of May 2026.

The company specializes in designing, manufacturing, and marketing surgical devices and biologics for the treatment of bunion and related midfoot deformities. Its flagship product is the patented Lapiplasty® 3D Bunion Correction® System, which aims to correct bunions in three anatomical planes by addressing the root cause of the deformity. Treace Medical Concepts' product portfolio also includes the Adductoplasty® Midfoot Correction System, SpeedMTP™ Rapid Compression Implant, Nanoplasty™ 3D Minimally Invasive Bunion Correction System, Percuplasty™ Percutaneous 3D Bunion Correction System, and SpeedPlate™ Rapid Compression Implants.

Based on the provided patent litigation data, Treace Medical Concepts Inc. has appeared as a defendant in one tracked case and has no tracked plaintiff cases. This indicates the company operates primarily as an operating company that defends against patent challenges. The sole tracked case, Unified Patents v. Treace Medical Concepts Inc., occurred before the Patent Trial and Appeal Board (PTAB), suggesting a challenge to the validity of one of its patents.

In a broader context, Treace Medical Concepts actively protects its intellectual property, holding over 130 granted patents and more than 200 pending applications globally as of early 2026. The company has also stated its engagement in filing lawsuits against competitors for patent infringement to safeguard its innovations. In June 2023, Treace acquired certain assets of RedPoint Medical3D, including 22 patent applications, further expanding its patent portfolio.